Ra223 in Bone Metastases with Osteolytic Activity

Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Renato Patrizio, Cardile, Davide, Murabito, Alessandra, Tripoli, Vincenzo, Verderame, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905256/
https://www.ncbi.nlm.nih.gov/pubmed/29719487
http://dx.doi.org/10.4103/wjnm.WJNM_22_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905256/
https://www.ncbi.nlm.nih.gov/pubmed/29719487
http://dx.doi.org/10.4103/wjnm.WJNM_22_17

Ejemplares similares